Adiponectin Paradox as a Therapeutic Target in Alzheimer’s Disease

Despite the apparent neurotoxicity of amyloid-β (Aβ), recent clinical trials of Aβ immunotherapy have not shown any clinical benefit in Alzheimer’s disease (AD). Given this, clarification of the next generation therapeutic strategy in AD is warranted. Hypothetically, adiponectin might be involved in...

Descripción completa

Detalles Bibliográficos
Autores principales: Waragai, Masaaki, Ho, Gilbert, Takamatsu, Yoshiki, Wada, Ryoko, Sugama, Shuei, Takenouchi, Takato, Masliah, Eliezer, Hashimoto, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504987/
https://www.ncbi.nlm.nih.gov/pubmed/32623396
http://dx.doi.org/10.3233/JAD-200416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504987/
https://www.ncbi.nlm.nih.gov/pubmed/32623396
http://dx.doi.org/10.3233/JAD-200416

Ejemplares similares